EP
PCRX icon

Essential Partners’s Pacira BioSciences PCRX Stock Holding History

Essential Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.4K Hold
134
– – ﹤0.01% 1726
2026
Q1 		$3.03K Hold
134
– – ﹤0.01% 1819
2025
Q4 		$3.47K Hold
134
– – ﹤0.01% 1583
2025
Q3 		$3.45K Hold
134
– – ﹤0.01% 1576
2025
Q2 		$3.2K Buy
+134
New +$3.38K ﹤0.01% 1178

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's PCRX Position: Q2 2026 in Review

Essential Partners held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 134 shares worth $3.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

Essential Partners first reported a position in PCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.47K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Essential Partners held 134 shares of Pacira BioSciences worth $3.4K as of Q2 2026.
  • Essential Partners left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1726 holding.
  • Essential Partners first reported a position in Pacira BioSciences in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Pacira BioSciences position peaked at $3.47K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.